Clinical considerations - opicapone.PNG (67.15 kB)

Opicapone: a review in Parkinson's disease

Download (67.15 kB)
online resource
posted on 11.01.2021, 20:01 by Lesley J. Scott

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable



Additional information about this Adis Drug Review can be found here.


Abstract

Oral opicapone (Ongentys®), a potent third-generation, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved in several countries for use as adjunctive therapy to preparations of levodopa/dopa-decarboxylase inhibitor (L-dopa/DDCI) in adults with Parkinson’s disease (PD) and end-of dose (EoD) motor fluctuations; specific indications vary between individual countries. In pivotal global, randomized, controlled trials (BIPARK 1 and BIPARK 2; 14–15 weeks’ duration), open-label extensions (OLEs) of BIPARK, and in the real-world setting (OPTIPARK; 3–6 months), opicapone 50 mg once daily was an effective and generally well tolerated adjunctive therapy to L-dopa/DDCI plus other PD therapy in adults with PD and EoD motor fluctuations. Adjunctive opicapone provided better efficacy than placebo for improvements in ON- and OFF-state time and fulfilled noninferiority to adjunctive entacapone for improvements in OFF time in the clinical trial setting. These beneficial effects of adjunctive opicapone on motor fluctuations were maintained during 1 year of treatment in OLE studies. Given its efficacy and safety profile, adjunctive opicapone remains an important option in the management of adults with PD and EoD motor fluctuations who cannot be stabilized on preparations of L-dopa/DDCI.


© Springer Nature Switzerland AG 2020

History

Exports

Read the peer-reviewed publication

Logo branding

Categories

Exports